Recently, Willemse et al. showed that neurogranin did not differentiate AD from non-AD dementia in two dementia cohorts, one included clinical AD and non-AD patients with high CSF tau levels and the other included patients with a definite post-mortem diagnosis, independently from CSF biomarkers [34]. This evidence concerns the gene MAPT and dementia.